Stock Analysts

MeadWestvaco, Rock-Tenn Announce Merger Completion Date

MeadWestvaco Corporation MWV and Rock-Tenn Company RKT have announced a date for special meetings of their respective shareholders to approve their previously announced merger, which is likely to be completed by Jul 1, 2015. Shares of MeadWestvaco gained 1.15% on the news. Following the merger, MeadWestvaco and RockTenn will become subsidiaries of WestRock Company, the new company that will be formed from their combination, as named by the former two earlier this month. […]

Stock Analysts

Will SAP Regain Growth on Rising Adoption of HCM Solution?

Of late, leading enterprise application software company SAP SE ’s SAP ‘SuccessFactors’ seems to be the magic answer to the prayers of large multinational companies’ human resource management ("HRM") problems. SuccessFactors, a SAP company specialized in providing cloud-based human capital management (“HCM”) solution, has been gaining an increasing number of clients in the U.S. market […]

Stock Analysts

Barrick Gold (ABX) to Divest Cowal Mine for $550 Million

Barrick Gold Corporation ABX has entered into a deal to sell the Cowal mine in New South Wales, Australia to Evolution Mining for $550 million in cash on closing. The transaction is expected to conclude in the third quarter of 2015, subject to customary closing conditions. The sale is in sync with Barrick’s strategy of creating long-term value for shareholders as it would contribute considerably to the company’s debt reduction target and allow it to focus on expanding the geographic footprint of its portfolio. […]

Stock Analysts

SunEdison to Grow in California with 33 MW Rooftop Arrays

SunEdison Inc. SUNE , the world’s leading renewable energy developing company, is benefitting from the rising global demand for cheap and clean energy. Recently, the company announced that it has been awarded a contract to build 33 megawatts (MW) of rooftop arrays in Southern California by Southern California Edison – a subsidiary of Edison International EIX . […]

Stock Analysts

Banks Face Probe over Automated FX Trading Manipulation

After the resolution of foreign exchange (“FX”) market rigging probe , major banks are now bracing themselves for penalties from the New York Department of Financial Services (“DFS”), as a result of investigations over manipulation of automated FX trading. The news was first reported by The Financial Times. […]

Stock Analysts

Lincoln National (LNC) Falls Despite Rise in Share Buyback

Lincoln National Corporation ’s LNC board of directors recently sanctioned an increase in its share repurchase program to $1.0 billion. The board also declared a quarterly cash dividend of 20 cents per share. The company’s share price, however, has been trending downward post announcement and has shown a 1.04% fall in the last two trading sessions, finally closing at $58.61 per share on May 22. […]

Stock Analysts

Vulcan Materials Demand Trends Strengthen: Time to Invest?

On May 21, we issued an updated research report on Vulcan Materials Company VMC . Vulcan Materials’ first-quarter 2015 (results announced on May 5) adjusted loss of 16 cents per share was narrower than the Zacks Consensus Estimate as well as the year-ago loss on the back of solid aggregates volume, increasing pricing momentum and lower diesel costs. Revenues in the key aggregates segment grew 17.4% driven by continued strong demand growth and increasing pricing momentum in the segment. […]

Stock Analysts

Pebblebrook Hotel (PEB) Buys LaPlaya Property in Naples

With an aim to expand its portfolio in the booming market of Naples, FL, Pebblebrook Hotel Trust PEB announced the acquisition of LaPlaya Beach Resort and LaPlaya Beach Club for $185.5 million. However, per the agreement, Noble House Hotels & Resorts will continue to manage the LaPlaya portfolio. The acquisition is expected to be accretive for the Bethesda, MD-based real estate equity trust (“REIT”), going forward. […]

Stock Analysts

CF Industries (CF) Strikes Fresh 52-Week High at $322.39

Shares of CF Industries CF touched a new 52-week high of $322.39 on May 22, exceeding the previous high of $320.57. The stock pulled back to close the day at $320.92. The fertilizer maker, which has a market cap of around $15.1 billion, has seen its shares rise roughly 34% over the past year. […]

Stock Analysts

ArcelorMittal Inks MoU with SAIL for Automotive Steel Unit

ArcelorMittal MT has signed a Memorandum of Understanding (“MoU”) with India’s leading steel company – the Steel Authority of India (“SAIL”) – for setting up an automotive steel producing unit in the country, under a joint venture arrangement. The MoU was jointly signed by Lakshmi Mittal, Chairman and CEO of ArcelorMittal, and C.S. Verma, Chairman of SAIL, in the presence of Rakesh Singh, Secretary to the Government of India, Ministry of Steel, and Aditya Mittal, ArcelorMittal CFO and CEO ArcelorMittal Europe […]

Stock Analysts

Hibbett (HIBB) Misses Q1 Earnings, Sales; Lowers Guidance

Hibbett Sports, Inc. HIBB began fiscal 2016 on a disappointing note as this Zacks Rank #4 (Sell) company posted lower-than-expected top and bottom-line results for the first quarter. Hibbett’s quarterly earnings of $1.09 per share missed the Zacks Consensus Estimate of $1.14, but remained flat year over year […]

Stock Analysts

Amgen’s PCSK9 Inhibitor a Step Closer to EU Approval

Amgen AMGN is a step closer to gaining EU approval for its cholesterol management candidate, Repatha (evolocumab) with the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) recommending the approval of the experimental treatment in certain patients with high cholesterol. The positive opinion covers the use of Repatha for the treatment of adults with primary hypercholesterolemia (heterozygous familial and non-familial [HeFH]) or mixed dyslipidemia, as an adjunct to diet in combination with a statin or a statin with other lipid-lowering therapies in patients unable to reach LDL-C (bad cholesterol) goals with the maximum tolerated dose of a statin, or alone or in combination with other lipid-lowering therapies in patients who are statin-intolerant, or for whom a statin is contraindicated. Repatha also received a positive opinion for use in the treatment of adults and adolescents (12 years and above) with homozygous familial hypercholesterolemia (HoFH) in combination with other lipid-lowering therapies […]